EHA 2024
Featured articles
Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials
CONTENTS
Online First
Multiple Myeloma
Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial
PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM
Post-intensification data confirm superiority of quadruple therapy in MM
Promising phase 1 results for novel CAR T-cell therapy in MM
DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM
Leukaemia
PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL
APOLLO: ATRA plus ATO meets expectations in high-risk APL
Excellent phase 3 results for asciminib in chronic myeloid leukaemia
AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy
FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML
CD40/CD47 inhibitor shows promise in high-risk MDS and AML
ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS
Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?
Can WGTS replace standard-of-care diagnostics in AML?
Non-malignant Haematology
ENERGIZE: Mitapivat meets primary efficacy endpoint in thalassaemia
Sovleplenib delivers durable responses and QoL improvements in primary ITP
Avatrombopag successful in children with chronic ITP
RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease
Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis
Myelofibrosis
Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis
Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis?
Lymphoma
The landscape of TP53 mutations and their prognostic impact in CLL
Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?
High survival rates following atezolizumab consolidation in DLBCL
First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL
EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation
Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes
